Evidence map›Paper›PMID 28840310›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2017

Topical cis-urocanic acid prevents ocular surface irritation in both IgE -independent and -mediated rat model.

Hanna-Mari Jauhonen, Jarmo Laihia, Olli Oksala, Johanna Viiri, Reijo Sironen, Päivi Alajuuma, Kai Kaarniranta, Lasse Leino

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Ternary Cu(II) Complex with GHK Peptide andInternational journal of molecular sciences · 2020
    Article
  4. Emerging Therapeutics for Ocular Surface Disease.Current allergy and asthma reports · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hanna-Mari JauhonenDepartment of Ophthalmology, Kuopio University Hospital, Kuopio, Finland. hanna-mari.jauhonen@kuh.fi.ORCID http://orcid.org/0000-0003-3972-2134
Jarmo LaihiaBioCis Pharma Ltd, Turku, Finland.
Olli OksalaSanten Oy, Tampere, Finland.
Johanna ViiriInstitute of Clinical Medicine, Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland.
Reijo SironenInstitute of Clinical Medicine, Department of Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.
Päivi AlajuumaSanten Oy, Tampere, Finland.
Kai KaarnirantaDepartment of Ophthalmology, Kuopio University Hospital, Kuopio, Finland.
Lasse LeinoBioCis Pharma Ltd, Turku, Finland.
University of Eastern Finland · FISanten (Finland) · FITurku Centre for Biotechnology · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur purpose was to investigate the effect of locally administered cis-urocanic (cis-UCA) in two experimental models of allergic conjunctivitis.

methodsThe compound 48/80 (C48/80)-induced ocular irritation model (IgE-independent) and the ovalbumin (OA)-induced ocular allergy model (IgE-mediated) were used to test and compare the effect of cis-UCA on dexamethasone, ketotifen and olopatadine. In the C48/80 model, clinical severity scoring from photographs, immunohistochemical analysis of nuclear Ki-67 antigen to quantify actively proliferating epithelial cells and of caspase-3 enzyme to identify apoptotic activity in the conjunctival tissue were used. In the OA model, an Evans Blue stain concentration of conjunctival tissue was used to evaluate vascular leakage due to allergic reaction.

resultsThe cis-UCA was well tolerated and effective in both the IgE-independent and -mediated rat models. Treatment with C48/80 caused conjunctival hyperaemia, which was significantly inhibited by ketotifen at the 6 h time point (p = 0.014) and by dexamethasone and cis-UCA 0.5% at 12 (p = 0.004) and 24 (p = 0.004) hour time points. In a comparison between the active drug treatments, only ketotifen showed a significant difference (p = 0.023) to cis-UCA treatment at the 1 h time point, otherwise there were no statistically significant differences between the active drugs. Ketotifen, dexamethasone and cis-UCA 0.5% significantly inhibited the C48/80-induced nuclear accumulation of Ki-67, without differences between the active treatment groups. In the OA model, cis-UCA 0.5% did not inhibit the vascular leakage of conjunctiva, whereas cis-UCA 2.5% of was at least equally effective compared to olopatadine, abolishing the allergic vascular leakage response almost completely.

conclusionsThe present findings in the two AC models suggest that cis-UCA might have anti-allergic potency both in immediate and delayed-type allergic reactions in the eye.

Indexed as

Administration, TopicalAnimalsAntibodies, Anti-IdiotypicConjunctivitis, AllergicDisease Models, AnimalImmunoglobulin EOleic AcidsOphthalmic Solutionsp-Methoxy-N-methylphenethylamineRatsRats, Sprague-DawleyRats, WistarAntibodies, Anti-Idiotypiccis-vaccenic acidImmunoglobulin EOleic AcidsOphthalmic Solutionsp-Methoxy-N-methylphenethylamineAllergic conjunctivitisCis-urocanic acidExperimental animal modelOcular allergy

Identifiers

PMID28840310
OpenAlexW2748641725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.